10:59 AM EDT, 06/03/2024 (MT Newswires) -- uniQure (QURE) shares rose 8% in recent Monday trading after the company obtained the regenerative medicine advanced therapy designation from the US Food and Drug Administration for AMT-130 to treat Huntington's disease.

The move is based on the potential of the investigational gene therapy to address the major unmet medical need among people with the disease, the company said Monday. The designation follows after the comparison of two-year AMT-130 data with a natural history group.

The designation was created to expedite the development and review process of regenerative medicine therapies, uniQure said.

The company said it expects to release interim results from phase 1/2 US and European trials of AMT-130 in the middle of this year.

Price: 5.34, Change: +0.39, Percent Change: +7.97